Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.39 |
| ▸ | GSR | P00390 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089367 | 1.00 | MAPT (0.39) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL23612096 | 0.80 | PDE10A (0.37) | MAPTTDP1POLBL3MBTL1PDE10A | |
| SCHEMBL30166996 | 0.80 | PDE10A (0.37) | MAPTTDP1POLBL3MBTL1PDE10A | |
| SCHEMBL28967658 | 0.78 | ALDH1A1 (0.37) | MAPTTXNRD1TDP1POLBL3MBTL1 | |
| SCHEMBL28935509 | 0.76 | MEN1 (0.35) | MAPTL3MBTL1PDE10AALDH1A1MEN1 | |
| SCHEMBL30166982 | 0.76 | TXNRD1 (0.47) | MAPTTXNRD1GSRHTTMAPK1 | |
| SCHEMBL23166407 | 0.76 | TXNRD1 (0.47) | MAPTTXNRD1GSRHTTMAPK1 | |
| SCHEMBL30019384 | 0.76 | MEN1 (0.35) | MAPTL3MBTL1PDE10AALDH1A1MEN1 | |
| SCHEMBL29229030 | 0.75 | PIN1 (0.41) | KDM4EPIM3 | |
| SCHEMBL3169007 | 0.75 | PDE10A (0.53) | MAPTTDP1POLBL3MBTL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-13 | — | — | US | disclosed |
| CN-115768761-A | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| EP-4129406-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4085061-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
| CN-101801194-A | Has 5-HT 63 ' the compound that replaces of receptor affinity | MEMORY PHARM CORP | 2010-08-11 | — | — | CN | disclosed |
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | MAPT 4091/4885MERTK 3372/4885TXNRD1 2437/4885 |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAPT 3027/4885MERTK 1396/4885TXNRD1 1317/4885 |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | MAPT 4782/4885MERTK 2076/4885TXNRD1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.